Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    PLoS pathogens · 2021
    LFLars F Westblade
    PMID: 34855921PMCID: PMC8638991DOISenior author61 citations
  2. 2
    Cancer cell · 2020
    LFLars F WestbladeLPLaura PinheiroPGParag GoyalMPMarkus Plate+6 more →MSMichael Satlin
    PMID: 32997958PMCID: PMC7492074DOIFirst author187 citations
  3. 3
    Journal of clinical microbiology · 2020
    LFLars F Westblade
    PMID: 33115842PMCID: PMC7771434DOISenior author19 citations

Publications

198 publications

Funding

22 grants

Active

8 grants
  • Sub-PI
    Bactericidal Hydrogels for Bone Repair
    National Inst of Arthritis & Musculoskeletal & Skin Diseases · 2024–2029 · via Georgia Institute of Technology
    R01AR083702-03
  • Sub-PI
    Development of Targeted Antipseudomonal Bactericidal Prodrugs
    National Institute of Allergy and Infectious Diseases · 2023–2028 · via Cornell University - Ithaca
    R01AI174461-04
  • PI
    Hardy Diagnostics and NG Biotech NG-TEST® Candida auris Research Agreement
    Hardy Diagnostics · 2026–2027Contract
    HD 263836-01
  • Sub-PI
    Combatting Hospital-Acquired Carbapenem-Resistant Organism Infections in Cats
    EveryCat Health Foundation · 2026–2027 · via Cornell University
    CU 256123-01
  • Co-I
    Screening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic Patients
    National Institute of Allergy and Infectious Diseases · 2024–2027
    R21AI182845-02
  • Co-I
    In vitro Activity of Delafloxacin Against Viridians Group Streptococci Isolated from Neutropenic Patients
    Melinta Therapeutics, Inc. · 2026–2026Contract
    SRA 253345-01
  • Co-I
    "Multi-Drug Resistant Organism Network" (MDRO NETWORK)
    National Institute of Allergy and Infectious Diseases · 2019–2026 · via Duke University
    UM1AI104681-08
  • Co-I
    Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantation
    National Institute of Allergy and Infectious Diseases · 2020–2026 · via Cornell University - Ithaca
    R01AI151059-02
Completed grants (14)
  • Co-I
    Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic Patients
    National Institute of Allergy and Infectious Diseases · 2020–2025
    R01AI151038-04
  • PI
    "Performance comparison of rapid Antimicrobial Susceptibility Test (AST) system for clinical isolate colonies" SRA with Selux Diagnostics
    Selux Diagnostics · 2022–2024Contract
    SA 225932-01
  • PI
    Hardy/NG Biotech CTX-M Study
    Hardy Diagnostics · 2023–2024Contract
    SA 233773-01
  • Co-I
    Cell-Free DNA in Peritoneal Fluid as a Novel and Versatile Analyte for Monitoring Peritonitis
    National Institute of Allergy and Infectious Diseases · 2021–2024
    R21AI164093-01
  • PI
    Clinical utility of viral load quantification in influenza infections
    Cornell University - Ithaca · 2022–2023
    CU 228234-01
  • Co-I
    Predicting Infections in Neutropenic Hosts Receiving Fluoroquinolone Prophylaxis
    National Institute of Allergy and Infectious Diseases · 2020–2023
    R03AI146612-01A1
  • Co-I
    DETECTION OF IMPENDING INFECTIONS IN IMMUNOCOMPROMISED CANCER PATIENTS.
    Starr Cancer Consortium · 2020–2022
    I13-0013
  • Sub-PI
    Targeted Macromolecular Antimicrobial Prodrugs against Pseudomonas aeruginosa
    National Institute of Allergy and Infectious Diseases · 2020–2022 · via Cornell University - Ithaca
    R21AI154102-02
  • PI
    Multicenter Evaluation of Detection of SARS-CoV-2 on the cobas® Liat® System
    Roche Molecular Systems, Inc. · 2020–2022Contract
    SRA 204685-01
  • PI
    Performance Evaluation of the LifeScale AST Rapid, Automated Antimicrobial Susceptibility System
    Affinity Biosensors LLC · 2020–2022Contract
    SRA 201975-01
  • PI
    Determining the role of antibiotic tolerance in antibiotic therapy failure
    Weill Cornell Medical College · 2021–2021
    WCMC 211765-01
  • Co-I
    Multiplex PCR Characterization of Gastrointestinal Pathogens in Immunosuppressed Transplant Patient
    BioFire Diagnostic, LLC · 2018–2021
    SRA 181751-01
  • Co-I
    cobas® vivoDx MRSA Early Evaluation Program (EEP)
    Roche Molecular Systems, Inc. · 2020–2021Contract
    SRA 202240-01
  • Co-I
    Peritoneal Fluid Microbiome Predictive of Peritonitis
    National Kidney Foundation, Inc. · 2017–2019
    NKF 17091294-01

External relationships

Advisory/Scientific Board Member

Shionogi & Co., Ltd